Search clinical trials for: Technosphere® Insulin

Total 16219 results

Mannkind Corporation

Completed

Compare the Same Dosage of Insulin Using a Combination of Cartridges, 30 Units as 2 Cartridges vs. 1 Cartridge

Healthy Volunteers

United States
Mannkind Corporation

Completed

Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States, Russian Federation, Brazil, Ukraine
Mannkind Corporation

Completed

A Study Designed to Compare 2 Dose Strengths of TI Inhalation Powder in Adults With Type 1 Diabetes Mellitus and to Compare One of Those Formulations (30Units) With an Injection of Insulin Lispro

Diabetes Mellitus: Type 1

United States
Mannkind Corporation

Completed

Clinical Trial Evaluating Technosphere® Insulin Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Over a 24-week Treatment Period

Type 1 Diabetes Mellitus

United States, Brazil, Russian Federation, Ukraine
Mannkind Corporation

Completed

A Study to Evaluate Insulin in the Blood After Inhalation of a Dry Powder Insulin Formulation (Called Technosphere®/Insulin) in Non-diabetic Patients With & Without Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Netherlands, United States, Austria, United Kingdom
Mannkind Corporation

Completed

Comparison of the Effect on the Glucose Infusion Rates Between Inhaled Technosphere Insulin and a Subcutaneous Injection of Regular Human Insulin

Healthy
South Orange County Endocrinology
Mannkind Corporation

Withdrawn

Single Site, Single Subject, Treatment IND With Mannkind Corporation's Technosphere Inhalation System

Diabetes

United States
Mannkind Corporation

Completed

Study of the Efficacy and Safety of Inhaled Technosphere Insulin in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus
Mannkind Corporation

Completed

Pharmacokinetic Study in Healthy Volunteers

Healthy Volunteers

United States
Mannkind Corporation

Completed

PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)

Type 1 Diabetes Mellitus

Germany
Mannkind Corporation

Terminated

Evaluate Safety of Technosphere® Insulin (TI) in Diabetic Subjects With Moderate Obstructive Pulmonary Disease

Type 2 Diabetes Mellitus | Asthma | Type 1 Diabetes Mellitus | Moderate Chronic Obstructive Pulmonary Disease

United States, Russian Federation, Ukraine
Mannkind Corporation

Completed

18-Week, Randomized, Double-blind, Placebo Controlled, Forced Titration Study of Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus
Mannkind Corporation

Completed

Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes

Diabetes, Type 2 | Diabetes, Type 1

United States, Spain, Canada, Russian Federation, Czech Republic, Poland, Ukraine, United Kingdom
Mannkind Corporation

Completed

Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Brazil, Spain, Argentina, Canada, Chile, Mexico, Poland, Russian Federation, Ukraine, Czech Republic
Mannkind Corporation

Terminated

Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Inhalation Insulin (TI) Inhalation Powder Using the Gen2 Inhaler

Type 2 Diabetes

United States
Mannkind Corporation

Completed

An Open-label, Multi-center, International, Three-year, Safety and Tolerability 'Follow on' Trial

Type 2 Diabetes Mellitus

United States, Czech Republic, Bulgaria, Germany
Mannkind Corporation
Jaeb Center for Health Research

Active, not recruiting

Afrezza® INHALE-1 Study in Pediatrics (INHALE-1)

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1

United States
Mannkind Corporation

Completed

Effects of URI on Diabetic Subjects Utilizing Technosphere Insulin After a Meal Challenge

Diabetes Mellitus | Upper Respiratory Infection

United States, Russian Federation, Canada
Mannkind Corporation

Completed

A Study Comparing Subcutaneous Rapid Acting Insulin and One Formulation of Inhaled Insulin in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Mannkind Corporation

Terminated

Inhaled Technosphere Insulin in Subjects With Diabetes Mellitus and Asthma

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Asthma

Brazil, United States, Canada, Poland, Russian Federation, Argentina, Czech Republic, Mexico, Spain, Ukraine, United Kingdom
Mannkind Corporation

Completed

To Compare the Effect of Inhaled Insulin With Subcutaneously Injected Insulin in Subjects With Type 2 Diabetes Mellitus.

Diabetes Mellitus, Type 2

Germany
Mannkind Corporation

Completed

Comparison Between Technosphere/Insulin Inhalation Powder Versus Rapid Acting Insulin in Subjects With Type 2 Diabetes Mellitus

Diabetes Type 2

Russian Federation
University of Colorado, Denver
University of Southern California; Mannkind Corporation; Atlanta Diabetes Associates and other collaborators

Completed

Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study (STAT)

Diabetes Mellitus, Type 1

United States
Mannkind Corporation

Completed

A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine

Diabetes Mellitus, Type 1
Sansum Diabetes Research Institute
Juvenile Diabetes Research Foundation

Completed

Feasibility Study Using Zone-MPC Controller, HMS and Technosphere® Insulin Inhalation System From MannnKind Corp

Type 1 Diabetes Mellitus

United States
Mannkind Corporation

Completed

Afrezza Safety and Pharmacokinetics Study in Pediatric Patients

Type 1 Diabetes Mellitus

United States
Mannkind Corporation

Completed

Efficacy & Safety of Inhaled Insulin in Type 1 Diabetes

Diabetes, Type I

United States, Spain, Brazil, Argentina, Canada, Chile, Mexico, Poland, Russian Federation, United Kingdom
Mannkind Corporation

Completed

Clamp Study Comparing Inhalation of Technosphere®/Insulin in Smokers and Non-Smokers With Type 2 Diabetes

Diabetes Type 2

United States
Mannkind Corporation

Completed

A 2-Month Safety Follow-Up Trial

Type 1 Diabetes | Type 2 Diabetes

United States, Brazil, Canada, Russian Federation
Geropharm

Completed

Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients

Diabetes Mellitus, Type 2

Russian Federation
Mannkind Corporation

Completed

Bioavailability of Technosphere® Insulin Versus Subcutaneous Regular Human Insulin in Type 2 Diabetes

Type 2 Diabetes Mellitus
Mannkind Corporation

Terminated

Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

Diabetes, Type 1

United States, Brazil
Mannkind Corporation

No longer available

Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder

Type 1 Diabetes | Type 2 Diabetes

United States
Mannkind Corporation

Completed

Single Dose Clamp Study to Evaluate Concentration-time Profile and Metabolic Activity of 3 Dose Levels of Afrezza and 3 Dose Levels of Insulin Lispro in Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Germany
Mannkind Corporation

Completed

Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler

Healthy

United States
Mannkind Corporation

Completed

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

Diabetes Type 2

Brazil, Spain, United States, Argentina, Canada, Chile, Mexico, Poland, Russian Federation, United Kingdom
Mannkind Corporation

Completed

Comparison of Technosphere Insulin Inhalation Powder & Subcutaneous Rapid-Acting Analog in Subjects With Type 1 Diabetes

Type 1 Diabetes Mellitus

United States
Mannkind Corporation

Terminated

Pulmonary Function Substudy for Subjects Enrolled in Studies MKC-TI-161, MKC-TI-162 or MKC-TI-166

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

United States
Mannkind Corporation

Completed

Afrezza With Basal Combination (ABC)

Type 1 Diabetes

United States
Wockhardt

Terminated

Immunosafety Study of Recombinant Human Insulins in Type 1 Diabetics

Type I Diabetes

United States, India
Mannkind Corporation
Jaeb Center for Health Research

Active, not recruiting

INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Geropharm

Completed

Comparative Study of the Pharmacokinetics of Rinsulin® Mix 30/70, Suspension for Subcutaneous Administration, 100 IU / ml (OJSC GEROPHARM-Bio, Russia) and Humulin® M3, Suspension for Subcutaneous Administration, 100 IU / ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method

Bioequivalence

Russian Federation
Geropharm

Completed

A Study to Compare Pharmacokinetics and Pharmacodynamics of GP-40081 to NovoMix® 30 Penfill® in Healthy Subjects

Clamp Study

Russian Federation
Geropharm

Completed

Comparative Study of Rinsulin R (GEROPHARM) and Humulin Regular (Eli Lilly) Euglycemic Hyperinsulinemic Clamp Method

Bioequivalence | Therapeutic Equivalency

Russian Federation
Novo Nordisk A/S

Completed

Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes (INTENSIV)

Diabetes Mellitus, Type 2 | Diabetes

Austria
Novo Nordisk A/S

Completed

Observational Study on the Effect of NovoMix® 30, Levemir® or NovoRapid® (Alone or Combined) in Type 2 Diabetics Previously Treated With Anti-diabetic Medication (A1chieve®)

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, Algeria, Argentina, Bangladesh, China, Egypt, India, Indonesia, Iran, Islamic Republic of, Jordan, Korea, Republic of, Libyan Arab Jamahiriya, Malaysia, Mexico, Morocco, Pakistan, Philippines, Russian Federation and more
Novo Nordisk A/S

Completed

Observational Study on Efficacy and Safety in Patients Using NovoMix® 30 for the Treatment of Diabetes (UPGRADE)

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Korea, Republic of
Sanofi

Completed

Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy (Insuman-C25-CN)

Type 2 Diabetes Mellitus

China
Novo Nordisk A/S

Completed

Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetics Failing on OADs

Diabetes Mellitus, Type 2 | Diabetes

United States
Julphar Gulf Pharmaceutical Industries
Profil Institut für Stoffwechselforschung GmbH

Completed

Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin 30/70 and Huminsulin® Profil III

Diabetes Mellitus

Germany

3

Subscribe